Intravenous Immunoglobulins as Immunomodulators in Autoimmune Diseases and Reproductive Medicine

Antibodies (Basel). 2023 Mar 2;12(1):20. doi: 10.3390/antib12010020.

Abstract

Intravenous administration of immunoglobulins has been routinely used for more than 60 years in clinical practice, developed initially as replacement therapy in immunodeficiency disorders. Today, the use of intravenous immunoglobulins (IVIGs) is embedded in the modern algorithms for the management of a few diseases, while in most cases, their application is off-label and thus different from their registered therapeutic indications according to the summary of product characteristics. In this review, we present the state-of-the-art use of IVIGs in various autoimmune conditions and immune-mediated disorders associated with reproductive failure, as approved therapy, based on indications or off-label. IVIGs are often an alternative to other treatments, and the administration of IVIGs continues to expand as data accumulate. Additionally, new insights into the pathophysiology of immune-mediated disorders have been gained. Therefore, the need for immunomodulation has increased, where IVIG therapy represents an option for stimulating, inhibiting and regulating various immune processes.

Keywords: Guillen–Barre syndrome; Kawasaki; SLE; anti-phospholipid syndrome; autoimmune diseases; immunomodulation; intravenous immunoglobulins (IVIGs); myositis; reproductive failure.

Publication types

  • Review